A field guide · 13 modality families · snapshot Sept 15, 2026

A field map of thirteen major ways to make a medicine.

The useful question isn't "which technology wins?" It's: what kind of biological problem does each tool solve—and what new failure mode does it create?

01 · BreakthroughThe people and insight behind the mapped platform wave.
02 · CapitalWhere major pharma bets show conviction.
03 · Proof + perilThe medicine that validated it—and the failure that keeps it honest.

Mechanism map

Pick a modality to open it

13 / 13 shown
No modality matches that search. Try a drug, company, disease, or mechanism.

Pattern recognition

The trade-offs hide in the delivery system

A high-level comparison for remembering the shape of the field. "Repeat dosing" describes the typical product model, not every asset.

Family
Manufacturing
Repeat dosing
Main reach
Defining bottleneck
Small molecules / degraders
Scalable chemistry
Usually yes
Often intracellular
Specificity + resistance
Antibodies / ADCs / bispecifics
Complex biologics
Yes
Cell-surface / extracellular
Immune & payload toxicity
Cells / gene therapy / editing
Most complex
Often one-time
Potentially durable
Delivery, safety, access
mRNA / siRNA / ASO
Sequence platform
Usually yes
Strongest in liver today
Delivery beyond liver
Radiopharma / viruses / microbiome
Specialized networks
Varies
Highly context-specific
Supply + reproducibility

About this project

About this map

Biotech professional exploring how medicines are made. This map tracks the major therapeutic modality families, their key players, and the clinical milestones that define them.

The goal is pattern recognition — understanding the trade-offs, delivery challenges, and investment signals that shape which platforms reach patients.